ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.12
-0.19%
Dow Jones
39,118.86
-0.12%
Gold vs US Dollar
2,328.225
0.12%
Brent Oil
85.205
0.11%
Bitcoin
63,516.12
1.35%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Zai Lab Ltd (ZLAB)

  7. Zai Lab Ltd (ZLAB) News

Zai Lab (ZLAB)

Zai Lab Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ZLAB
DateTimeSourceHeadlineSymbolCompany
18/06/202421:19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ZLABZai Lab Ltd
18/06/202421:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
11/06/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
11/06/202421:05Business WireZai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&DNASDAQ:ZLABZai Lab Ltd
22/05/202412:30Business WireZai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque PsoriasisNASDAQ:ZLABZai Lab Ltd
20/05/202405:21Business WireZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in ChinaNASDAQ:ZLABZai Lab Ltd
16/05/202421:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
16/05/202412:30Business WireZai Lab Announces Participation in May and June Investor ConferencesNASDAQ:ZLABZai Lab Ltd
15/05/202421:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
14/05/202418:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZLABZai Lab Ltd
14/05/202412:30Business WireZai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in ChinaNASDAQ:ZLABZai Lab Ltd
13/05/202401:20Business WireZai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPANASDAQ:ZLABZai Lab Ltd
08/05/202421:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZLABZai Lab Ltd
08/05/202421:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
08/05/202421:05Business WireZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate UpdatesNASDAQ:ZLABZai Lab Ltd
15/04/202412:30Business WireZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024NASDAQ:ZLABZai Lab Ltd
11/04/202412:30Business WireZai Lab Statement on Executive Management Team’s Agreement on Share ActivitiesNASDAQ:ZLABZai Lab Ltd
02/04/202412:30Business WireZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology ProgramsNASDAQ:ZLABZai Lab Ltd
01/04/202412:30Business WireZai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...NASDAQ:ZLABZai Lab Ltd
27/03/202413:29Business WireZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerNASDAQ:ZLABZai Lab Ltd
13/03/202423:05Business WireZai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid TumorsNASDAQ:ZLABZai Lab Ltd
06/03/202421:01Business WireZai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)NASDAQ:ZLABZai Lab Ltd
06/03/202412:30Business WireZai Lab Announces Participation in March Investor ConferenceNASDAQ:ZLABZai Lab Ltd
04/03/202421:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
27/02/202421:20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ZLABZai Lab Ltd
27/02/202421:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
27/02/202421:05Business WireZai Lab Announces Full-Year 2023 Financial Results and Recent Corporate UpdatesNASDAQ:ZLABZai Lab Ltd
08/02/202421:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
25/01/202421:15Business WireZai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024NASDAQ:ZLABZai Lab Ltd
10/01/202422:12Business WireZai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLCNASDAQ:ZLABZai Lab Ltd
 Showing the most relevant articles for your search:NASDAQ:ZLAB

Your Recent History

BIT
UC1H0Q
Unicredit Bank
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved